Raymond James Financial’s INmune Bio INMB Stock Holding History

Raymond James Financial’s Portfolio INMB Stock Details INMB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$288K	Sell	147,478 -65,517	-31%	-$135K	﹤0.01%	4888
2026 Q2	$347K	Buy	212,995 +9,750	+5%	+$13.5K	﹤0.01%	4740
2026 Q1	$230K	Sell	203,245 -7,433	-4%	-$10.6K	﹤0.01%	4817
2025 Q4	$329K	Sell	210,678 -57,782	-22%	-$103K	﹤0.01%	4514
2025 Q3	$556K	Sell	268,460 -65,017	-19%	-$149K	﹤0.01%	4062
2025 Q2	$770K	Sell	333,477 -48,564	-13%	-$356K	﹤0.01%	3737
2025 Q1	$2.98M	Sell	382,041 -93,510	-20%	-$743K	﹤0.01%	2691
2024 Q4	$2.22M	Buy	+475,551	New	+$2.48M	﹤0.01%	2889

Other funds holding INMB

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Westside Investment Management Santa Monica, California $785M AUM 29.89% 1-Year Est. Return

Raymond James Financial's INMB Position: Q3 2026 in Review

Raymond James Financial reduced its INmune Bio (INMB) stake by 31% in Q3 2026, selling an estimated $135K and leaving 147,478 shares worth $288K. The position accounts for ﹤0.01% of the portfolio, ranked #4888.

Raymond James Financial first reported a position in INMB in Q4 2024 and has held it in 8 quarters since. The position peaked at $2.98M in Q1 2025. 45 funds tracked by Wall St. Rank hold INMB as of Q3 2026.

Raymond James Financial held 147,478 shares of INmune Bio worth $288K as of Q3 2026.
Raymond James Financial sold 65,517 INmune Bio shares in Q3 2026, an estimated $135K.
INmune Bio made up ﹤0.01% of Raymond James Financial's portfolio in Q3 2026, its #4888 holding.
Raymond James Financial first reported a position in INmune Bio in Q4 2024 and has held it in 8 quarters since.
Raymond James Financial's INmune Bio position peaked at $2.98M in Q1 2025.
45 funds tracked by Wall St. Rank held INmune Bio as of Q3 2026.

Based on Raymond James Financial's 13F filing for Q3 2026, filed 12 Nov 2026.